Novo secures EU approval for oral Wegovy
9 Articles
9 Articles
The market for weaker treatments could enter a new stage after the European Union authorised the first GLP-1 tablet drug for the treatment of obesity and overweight. Up to now, therapies in this category were available almost exclusively as injections, such as Wegovy and Ozempic.
The European Commission has approved the first GLP-1 receptor agonist class oral medication for weight control. It will be easier to lose weight and fight this problem. It is about Wegovy in...
Those who shy away from the idea of a weight loss syringe could have an alternative in the future: the EU has also approved Wegovy as a tablet for the first time, but the new pill is not suitable for everyone.
What those considering Wegovy and Ozempic-type treatments should know.
Novo secures EU approval for oral Wegovy
Novo Nordisk has secured European Commission approval for an oral formulation of Wegovy, creating the first tablet-based GLP-1 weight management treatment authorised across the European Union. The once-daily medicine contains 25 mg of semaglutide and extends the Wegovy franchise beyond its established injectable presentation. Novo Nordisk reported a mean weight reduction of approximately 17% among adults who followed the treatment regimen in the…
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
